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ABSTRACT HER2 (ErbB2/Neu) is a receptor tyrosine kinase belonging to the epidermal growth factor receptor (EGFR)/ErbB
family and is overexpressed in 20–30% of human breast cancers. Although several crystal structures of ErbB kinases have been
solved, the precise mechanism of HER2 activation remains unknown, and it has been suggested that HER2 is unique in its
requirement for phosphorylation of Y877, a key tyrosine residue located in the activation loop. To elucidate mechanistic details
of kinase domain regulation, we performed molecular dynamics simulations of a homology-modeled HER2 kinase structure in
active and inactive conformations. Principal component analysis of the atomistic ﬂuctuations reveals a tight coupling between
the activation loop and catalytic loop that may contribute to alignment of residues required for catalysis in the active kinase.
The free energy perturbation method is also employed to predict a role for phosphorylated Y877 in stabilizing the kinase confor-
mations. Finally, simulation results are presented for a HER2/EGFR heterodimer and reveal that the dimeric interface induces
a rearrangement of the aC helix toward the active conformation. Elucidation of the molecular regulatory mechanisms in HER2
will help establish structure-function relationships in the wild-type kinase, as well as predict mutations with a propensity for consti-
tutive activation in HER2-mediated cancers.INTRODUCTION
HER2 (ErbB2/Neu) is a member of the ErbB family of trans-
membrane receptor tyrosine kinases, which also includes the
epidermal growth factor receptor (EGFR/ErbB1), ErbB3
(HER3), and ErbB4 (HER4). ErbB receptors are composed
of an extracellular ligand-binding domain, a transmembrane
segment, an intracellular protein tyrosine kinase domain, and
a C-terminal tail harboring tyrosine phosphorylation sites
(1). Under physiological conditions, ligand binding
promotes homo- or heterodimerization of the receptors and
activation of their cytoplasmic domains (2,3). Dimerization
results in auto- or transphosphorylation of tyrosine residues
in the C-terminal tail segments, which serve as docking sites
for signaling molecules containing SH2 or PTB domains (4).
The major signaling cascades activated by the ErbB family
include the Ras-Raf-MEK-MAPK and PI3K-Akt pathways,
both of which result in transcription of genes involved in
cellular proliferation, differentiation, and migration (5).
Aberrant activation of the ErbB network is frequently asso-
ciated with cellular transformation and clinical malignancies
such as lung, gastric, and breast cancers (6–12). Overexpres-
sion of HER2 results in constitutive, ligand-independent
activation of kinase signaling and is found in 20–30% of
human breast cancers, where it is correlated with an aggres-
sive tumor phenotype (13,14).
Activation of the ligand-binding domain of the ErbB
receptor triggers conformational changes within its
cytoplasmic domain. To effect phosphoryl transfer of the
g-phosphate of ATP to tyrosine residues on target substrates,
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0006-3495/09/03/2321/14 $2.00several key loops within the kinase domain must be appro-
priately positioned (15). Residues 844–850 in HER2
comprise the catalytic loop (C-loop), which is crucial in
facilitating the phosphoryl transfer. The aC helix (residues
761–775) and the nucleotide-binding loop, or N-loop (resi-
dues 727–732), are responsible for coordination of the
ATP and substrate tyrosine. The activation loop (A-loop)
comprises residues 863–884 and governs activation of the
kinase by regulating accessibility of the target substrate to
the C-loop. The A-loop undergoes a significant conforma-
tional extension upon activation, uncovering the catalytic
machinery and enabling binding of the tyrosine substrate
to the C-loop (16).
In most protein kinases, the activation loop assumes its
catalytically competent conformation only if it is first phos-
phorylated on a regulatory tyrosine residue within the A-loop
(17). The regulatory tyrosine residue is Y877 in HER2 and
Y845 in EGFR. Although phosphorylation of EGFR on
Y845 has been observed experimentally, phosphorylation
does not seem to be required for catalytic activity, as
EGFR possessing a Y845F mutation is fully active (18). In
contrast, the role of A-loop phosphorylation in HER2 is
controversial, as several studies have highlighted the impor-
tance of Y877 phosphorylation for kinase activity (19,20).
Xu et al. (21) reported that mutation of Y877 to phenylala-
nine in COS-7 cells results in decreased autophosphorylation
of Y1248, a tyrosine located in the C-terminal tail of HER2.
Therefore, it is possible that phosphorylation of Y877
augments HER2 kinase activity.
Several crystal structures of the extracellular and
cytoplasmic domains of the ErbB family members have
elucidated mechanisms of autoinhibition and activation
(16,22–28). Recent structural studies demonstrate that
doi: 10.1016/j.bpj.2008.12.3912
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dimerization mechanism analogous to that of a cyclin bound
to an activated cyclin-dependent kinase (CDK) (29,30). In
this asymmetric arrangement, the C-lobe of the activator
kinase interacts with the N-lobe of the CDK-like kinase, acti-
vating the CDK-like kinase through allosteric contacts. The
dimeric interface is dominated by hydrophobic interactions
between the C-lobe of the activator kinase and the aC helix
of the kinase undergoing activation. The dimerization model
postulates that all members of the ErbB family can serve as
the activating kinase, whereas only the catalytically compe-
tent members (EGFR, HER2, and ErbB4) can become acti-
vated. A sequence alignment of the ErbB kinase domains
reveals that the residues involved in the N- and C-lobe faces
of the dimer are essentially invariant among the family
members, suggesting that HER2 is likely to be activated
by a similar asymmetric dimerization scheme.
In this work we performed molecular dynamics (MD)
simulations of inactive and active HER2 structures to eluci-
date details of the mechanism by which the HER2 kinase
domain is regulated and activated. We investigated the
dimer-mediated allosteric activation of the HER2 kinase
through dynamics simulations of a HER2/EGFR heterodi-
meric system and delineated the role of phosphorylation of
the activation loop tyrosine residue, Y877, using the free
energy perturbation (FEP) method.
METHODS
Homology modeling of the HER2 kinase domain
The HER2 kinase domain was modeled in homology to EGFR, with which it
shares 83% sequence identity, using the program MODELLER (31,32). The
coordinates of the inactive EGFR kinase domain were downloaded from the
Protein Data Bank (PDB code 2GS7) (30) and a sequence alignment between
EGFR and HER2 was performed in MODELLER. Missing residues were
built using the loop modeling algorithm in MODELLER, and hydrogen
atoms were added by employing the hbuild routine in CHARMM27 (33).
The structure of the active HER2 kinase domain was based on the model
generated by Bagossi et al. (34). The Bagossi model, which was constructed
in homology to active EGFR (PDB code 1M14) (16), was refined by applying
the loop-modeling routine to segments of missing residues and performing
additional energy minimization steps. The final models for the inactive and
active HER2 kinase domains were assessed for stereochemical quality using
PROCHECK (35). Our homology models are indirectly validated in that the
crystal structure of ErbB4, a member of the ErbB family with relatively low
percentage sequence identity to EGFR (79%), was recently published (29)
and found to be structurally homologous to EGFR, with a root mean-square
deviation (RMSD) (backbone atoms) of 1.36 A˚ for the inactive EGFR and
ErbB4 structures, and 1.05 A˚ for the active structures.
MD simulations
Four different models of the HER2 kinase domain were constructed for anal-
ysis. Two models of the active conformation of the kinase were generated
(one in which Y877 is phosphorylated and one in which Y877 is unphos-
phorylated) and analogous models were constructed for the inactive confor-
mation. Each structure was explicitly solvated using the TIP3P model for
water (36) and with the buffering distance set to 15 A˚. Sodium (Naþ) and
chloride (Cl) ions were added to achieve net electroneutrality of the systemBiophysical Journal 96(6) 2321–2334and an ionic strength of 75 mM. All Naþ and Cl ions were placed at least
8 A˚ away from any protein atoms and from each other. The ions were posi-
tioned at points of electrostatic extrema using a Debye-Huckel potential
calculated within the program Solvate 1.0 (37). The Y877 residue was phos-
phorylated by applying the phosphotyrosine patch in CHARMM27 (33).
The entire system comprised 79,872 atoms for the active structure and
53,751 atoms for the inactive structure, the difference in system size being
attributed to the extension of the C-tail in the active system.
All simulations were performed with NAMD (38) using CHARMM27
force-field parameters. Periodic boundary conditions were applied and the
particle mesh Ewald algorithm (39) was adopted for the calculation of
long-range electrostatic interactions. The integration time step was set to
2.0 fs and the RATTLE algorithm (40) was employed to constrain the
lengths of all chemical bonds involving hydrogen atoms at their equilibrium
values. Nonbonded van der Waals (VDW) interactions were treated by
applying a switching function at 10 A˚ and truncating the VDW potential
energy smoothly at a cutoff distance of 12 A˚.
To prepare the system for MD simulation, the solvated structure was
energy-minimized using a conjugate gradient algorithm (NAMD) to remove
unfavorable contacts. The system was then heated to 300 K using the
temperature reassignment method in NAMD. Subsequently, constant pres-
sure and temperature (NPT) simulations were performed at 300 K and
1 atm to equilibrate the volume of the solvation box. Temperature and pres-
sure were maintained using a Langevin piston coupling algorithm (41). After
the NPT simulations, constant volume and temperature (NVT) simulations
were performed in NAMD. Finally, a 10 ns production run was completed
using the same parameters as the NVT simulations. All structural figures
were prepared with the program VMD (42).
Construction of the HER2/EGFR heterodimer
The HER2-EGFR heterodimeric system was modeled on the structure of the
EGFR homodimer published by Zhang et al. (30). The structure of the inac-
tive HER2 kinase domain was aligned with the activated kinase in the EGFR
homodimer, and the activating kinase (EGFR) remained in its crystallo-
graphically defined position. The structure was minimized to remove unfa-
vorable contacts, and hydrogen atoms were added using the hbuild routine in
CHARMM. The heterodimer was explicitly solvated using the TIP3P water
potential with the buffering distance set to 15 A˚ for a total system size of
124,093 atoms. Sodium (Naþ) and chloride (Cl) ions were added to
achieve net electroneutrality of the system and an ionic strength of 75 mM.
All Naþ and Cl ions were placed at least 8 A˚ away from any protein atoms
and from each other. Minimization and MD steps were performed as for the
monomeric systems, except that the production simulation was run for a total
of 20 ns.
Hydrogen-bonding analysis
CHARMM was used to analyze the hydrogen bonds present in the 10 ns
trajectory for each system. Hydrogen bonds were defined by a bond length
cutoff of 3.4 A˚ and an angle cutoff of 150. Bonds that fulfilled these criteria
and were present in at least 60% of the trajectory were tabulated in
CHARMM. Salt bridges were defined as hydrogen bonds occurring between
an acidic and a basic residue and satisfying a bond length cutoff of 1.6 A˚. All
hydrogen bonds and salt bridges were also visualized in VMD (42) for the
duration of the 10 ns simulation.
Calculation of the RMSD
The RMSD of the backbone atoms of the kinase domain was evaluated for
each frame of the 10 ns trajectory using the RMSD Plugin in VMD (42).
Each frame was aligned with the relevant reference structure, and the
RMS distance between the molecules was then measured. The initial, unmi-
nimized conformation was chosen as the reference structure for each system.
Calculations were performed for all backbone atoms as well as for specific
loops in the kinase domain, including the A-loop and the aC helix.
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A principal component analysis (PCA) was applied to each of the four
monomeric structures to identify the main eigenvectors (3N directions)
along which the majority of the complex motion is defined. The calculation
is based on the diagonalization of the variance-covariance matrix of the
atomic fluctuations along each MD trajectory to yield the set of eigenvectors
(PCs) and associated eigenvalues. The eigenvectors represent the indepen-
dent modes of atomic motion, and the eigenvalues reflect the contribution
of the corresponding eigenvectors to the global fluctuation of the protein.
PCA computes the covariance matrix as
sij ¼
ðxi  hxiiÞ

xj 

xj

;
where (i,j ¼ 1,.,3N), and N is the total number of atoms with positions
given by Cartesian coordinates x. The resulting matrix is diagonalized to
compute the 3N independent (uncorrelated) eigenvectors, {xi}, and the
eigenvalues, {li}, sorted in descending order. The angle brackets denote
the time average over the entire trajectory. All global translations and rota-
tions about the center of mass are removed before evaluation of s. PCA of
the HER2 structures was performed on an active site region that comprises
all domains critical for catalysis, including the A-, C-, and N-loops and the
aC helix. Specifically, the Ca atoms of the C-loop/A-loop region (residues
843–888) and the aC helix/N-loop region (residues 725–778) were chosen
as the active site, and the analysis was applied to the NVT-equilibrated
trajectory for each monomeric structure. The software program CARMA
(43) was used to perform PCA on our system and to project out the atomic
fluctuations due to the modes along the MD trajectory.
FEP simulations
The FEP method (44) was employed to compute the Helmholtz free energy
difference between the Y877-unphosphorylated and phosphorylated struc-
tures. Calculations were performed using the alchemical FEP feature in
NAMD (38,45). The Helmholtz free energy difference between two thermo-
dynamic states connected by M intermediate, nonphysical substrates in the
NVT ensemble is expressed as
DF ¼ 1
b
XMþ 1
i¼ 1
lnhexpf  b½nðx; liþ 1Þ  nðx; liÞgili
b ¼ 1
kBT
;
where kB is the Boltzmann constant, T is the temperature, and nðx; liÞ is the
potential energy function that depends on the Cartesian coordinates of the
system, {x}, and the coupling parameter, li, that connects the initial and
the final states of the transformation. The dual-topology paradigm (46)
was utilized, in which the initial and the final state are defined in terms of
distinct, noninteracting topologies. Four different simulations were per-
formed, including the transformation of Y877 to pY877 for the solvated un-
phosphorylated structures (inactive and active) and the transformation of
pY877 to Y877 for the solvated phosphorylated systems. Each perturbation
was divided into 48 windows with 20 ps of equilibration and 80 ps of data
collection per window, producing a total of 4.8 ns of simulation time for
each FEP transformation. Harmonic positional restraints were imposed on
the sodium and chloride ions, and system electroneutrality was maintained
by transforming counterions during the course of the alchemical perturba-
tion. Estimation of error was based on two different sets of coordinates
(i.e., the alchemical transformations were performed on configurations ob-
tained after 5 and 10 ns of MD trajectory), and errors are reported in terms
of the standard deviation from the mean DF. Another source of error
involves the end points of the transformation, which correspond to the crea-
tion or elimination of a group of atoms and are subject to VDW clashes that
result in end-point catastrophes (47,48). To obtain an accurate estimate ofthe free energy at the diverging end points, we increased the number of
windows at the beginning and end of the FEP simulations, collecting data
at several points with l values close to zero or one.
RESULTS
To elucidate the molecular mechanisms of kinase activation,
four different models of the HER2 kinase domain were con-
structed based on homology to EGFR (see the Methods
section and Fig. S1 (Supporting Material)). Two models of
the active conformation of the kinase were generated, one
in which Y877 is phosphorylated and one in which Y877
is unphosphorylated, and analogous models were con-
structed for the inactive conformation. Each solvated system
was subjected to MD simulation for 10 ns and the trajectories
were analyzed for conformational shifting as well as for key
bonding patterns. All four structures were stable for the dura-
tion of the simulation, as indicated by the time-course plots
of the RMSD of the backbone atoms in the A-loop and aC
helix (Fig. S2 and Fig. S3). The aC helix exhibited greater
fluctuations in the active systems but ultimately returned to
its initial position at the end of the 10 ns production run.
PCA reveals coupling between the catalytic loop
and the activation loop regions of the HER2 kinase
A PCA was applied to each of the four monomeric trajecto-
ries to characterize the global motions of the HER2 protein
(see the Methods section). The objective of this examination
was to delineate the differences in atomistic fluctuations
among the four structures, as conformational rearrangement
of the kinase domain is expected to correlate with dramatic
changes in the dynamical behavior of the protein. The PCA
calculation is based on the diagonalization of the variance-
covariance matrix of the atomic fluctuations along each
MD trajectory to yield the set of eigenvectors (PCs) and asso-
ciated eigenvalues. The eigenvectors represent the indepen-
dent modes of atomic motion, and the eigenvalues reflect
the contribution of the corresponding eigenvectors to the
global fluctuation of the protein. PCA of the HER2 structures
was performed on an active site region that comprises all
domains critical for catalysis, including the A-, C-, and
N-loops and the aC helix. Specifically, the Ca atoms of the
C-loop/A-loop region (residues 843–888) and the aC helix/
N-loop region (residues 725–778) were chosen as the active
site and the analysis was applied to the NVT-equilibrated
trajectory for each monomeric structure. Fig. S4 summarizes
the contributions of the top 10 PCs to the total motion of each
system, and reveals that the first three eigenmodes account
for the majority of the atomic fluctuations in each MD trajec-
tory. The top three PCs contribute 65% (both active and inac-
tive Y877-unphosphorylated structures; Fig. S4, A and B),
52% (Y877-phosphorylated active monomer; Fig. S4 C)
and 59% (Y877-phosphorylated inactive monomer; Fig. S4
D) to the total motion of the protein. Furthermore, the top
10 eigenmodes account for 75–85% of the total variationBiophysical Journal 96(6) 2321–2334
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well described by the top few eigenvectors.
In the Y877-unphosphorylated active structure, the first
principal motion involves a shifting of the aC helix in and
out of the active site, coupled with a tilting of the N-loop
(Fig. 1 A). In concert, the A-loop undergoes a slight bending
and the C-loop swings toward the N-loop (an animated image
is provided in Movie S1). Motion in the second eigenmode
also corresponds to concerted fluctuations of all four
domains: the aC helix tilts into the active site while the
C-loop and N-loop bend toward each other. In contrast, the
first and second eigenmodes for the inactive structure are
dominated by A-loop movement and reveal little correspond-
ing motion in the other loops, indicating that the four domains
are less coupled in the inactive system (see Fig. 1 B and
Movie S2). Analysis of the atomic fluctuations in the
Y877-phosphorylated trajectories reveals a similar distinc-
tion between the inactive and active structures (compare
Fig. 1,C andD; see also Movie S3 and Movie S4). We reason
that the interaction among the A-, C-, and N-loops and the aC
helix in the active systems is crucial for alignment of the key
domains for catalysis. The correlation between the A-loop
and C-loop is especially pronounced, ensuring appropriate
positioning of the catalytic aspartate, D845, and the coordi-
nating aspartate, D863, for the phosphoryl transfer reaction.
The normalized variance-covariance matrices for vector
displacements of atoms further emphasize and quantify the
interaction between the A-loop and C-loop in the active
system. Fig. 2 displays correlations between vector displace-Biophysical Journal 96(6) 2321–2334ments of atoms (d-hdi) for all four systems, where vector
d represents the displacement from the origin to the atom
of interest and hdi is the displacement averaged over all
frames in the trajectory. For both Y877-unphosphorylated
and Y877-phosphorylated structures, it is apparent that the
inactive and active systems differ in their respective correla-
tion patterns. The A-loop and C-loop exhibit high levels of
correlated atomic fluctuations in the active structures, as indi-
cated by the red/orange regions present at the intersection of
the A- and C-loop residues (Fig. 2, A and C). In contrast, the
A- and C-loop residues interface at cyan/green regions in the
cross-correlation plots for the inactive structures, signifying
a lack of concerted motion (Fig. 2, B and D). The expanded
figures (Fig. 2, E and F) highlight specific pairs of residues
that correspond to the intersection of the A- and C-loops in
the cross-correlation plots for the active structures. These
residue pairs, which include L866-R844 and Y877-R844,
may interact to couple the neighboring residues, D845 and
D863, in preparation for catalysis.
Rationalizing the differences in global motions
in terms of distinctive stabilizing bonding
networks in the active and inactive
conformations of the kinase
To identify specific interactions that could be contributing to
the differences in global motions of the inactive and active
systems, and investigate the mechanistic basis for the
coupling of the A- and C-loops, individual salt bridges andA
DC
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FIGURE 1 Global motions of the HER2 structures as
determined by the results of PCA. The structures represent
displacements along the first eigenmode for (A) the Y877-
unphosphorylated active system, (B) the Y877-unphos-
phorylated inactive system, (C) the Y877-phosphorylated
active system, and (D) the Y877-phosphorylated inactive
system. The structures are color-coded according to the
RMSD (red and white indicate large fluctuations, blue indi-
cates smaller fluctuations) to illustrate the motions in indi-
vidual residues. The four key domains move in a concerted
manner in the active system, whereas the inactive system
lacks such correlated fluctuations.
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FIGURE 2 Correlated fluctuations of
the Ca atoms in the active site region of
(A) the Y877-unphosphorylated active
system, (B) the Y877-unphosphorylated
inactive system, (C) the Y877-phos-
phorylated active system, and (D) the
Y877-phosphorylated inactive system.
The four key domains of the protein
(A-loop, C-loop, N-loop, and aC helix)
are labeled on the maps, and the regions
of high correlation between the C-loop
and A-loop are circled and magnified
in E and F. The color bars on the right
indicate the extent of the correlation as
quantified by the normalized correlation
coefficient. Residue pairs with a high
degree of correlated motion are shown
in yellow, orange, and red. Anticorre-
lated motions are represented by the
blue regions. Green and cyan regions
indicate little or no correlation.hydrogen bonds were tabulated for each of the four systems
through a hydrogen-bonding analysis of the 10 ns trajectories
(see Methods). The hydrogen bonds illustrated in Fig. 3 are
labeled according to the numbered residue pairs listed in
Table 1. Our analysis reveals that six hydrogen bonds occur
in the C-loop of the Y877-unphosphorylated active HER2
structure, the majority of which link the C-loop and A-loop
(Fig. 3 B and Table 1). Specifically, R844-L866, N850-
T862, V842-R868, and L852-K860 connect the C-loop to
the N-terminal end of the A-loop, and the L846-W888 bond
couples the C-loop and the C-terminal end of the A-loop. In
contrast, only two hydrogen bonds bridge the C-loop and
the A-loop in the Y877-unphosphorylated inactive HER2system (Fig. 3 A and Table 1). Analysis of the bonding
patterns in the Y877-phosphorylated trajectories reveals
a similar distinction between the inactive and active systems
(see Table S4). The extensive hydrogen bonding that prefer-
entially links the A- and C-loops in the active conformations
of the kinase provides a rationale for the cooperative fluctua-
tions between these regions, as revealed by the results of the
PCA. Indeed, the specific interactions that are identified in
the hydrogen-bonding analysis, including R844-L866 and
Y877-R844, also appear as correlated residue pairs in the
PCA cross-correlation plots (Fig. 2, E and F).
In cataloging the interactions, we compared the HER2
bonding network to that of EGFR and ErbB4 (49)Biophysical Journal 96(6) 2321–2334
2326 Telesco and RadhakrishnanFIGURE 3 Hydrogen-bonding analysis of the trajecto-
ries for the Y877-unphosphorylated systems in (A) the
inactive conformation and (B) the active conformation.
Labels correspond to the numbered residue pairs listed in
Table 1. Only those bonds that couple the key subdomains
of the kinase (A-loop, C-loop, and aC helix) are shown to
highlight the preferential bridging of the subdomains in the
active conformation. The A-loop is shown in red, C-loop in
purple, and aC helix in gray (color online).(Table S1, Table S2, and Table S3). An analysis of the
hydrogen bonds and salt bridges in the C-loop region of inac-
tive and active EGFR and ErbB4 reveals several similarities
to the HER2 bonding pattern. The active EGFR and ErbB4
structures each contain three bonds connecting to the A-
loop, whereas only one such bond occurs in each inactive
system (Table S2). Hence the similarity in the pattern of
specific interactions that preferentially bridge the A- and
C-loops in the active conformations of the EGFR, HER2,
and ErbB4 kinases suggests that the tight coupling of the
A- and C-loops may be a general feature of the architecture
of ErbB receptor kinases that likely aids in the assembly of
a catalytically competent active site.
TABLE 1 Hydrogen-bonding analysis of the MD trajectories
for the Y877-unphosphorylated HER2 kinase in the inactive and
active conformations
Label* Subregion Inactive HER2 Active HER2
1 aC helix — A763 HN, S760 OG
2 aC helix N764 HN, S760 O N764 HN, S760 O
3 aC helix — E766 OE1/2, R756 HE
4 aC helix/A-loop — E766, K883y
5 aC helix/A-loop — D769 OD1/2, R868 HH12
6 aC helix — E770, K753
7 aC helix Y772 O, G776 HN —
8 aC helix — V773 O, V777 HN
9 aC helix M774 O, L785 HN —
10 C-loop/A-loop V842 O, G865 HN —
11 C-loop/A-loop — V842 O/HN, R868 HN/0
12 C-loop/A-loop — R844 HE, L866 O
13 C-loop/A-loop — L846 O, W888 HE 1
14 C-loop A848 O, L807 HN —
15 C-loop/A-loop — N850 O, T862 HN
16 C-loop V851 O, L806 HN V851 O, L806 HN
17 C-loop/A-loop L852 HN, K860 O L852 HN, K860 O
18 A-loop D863, K753 —
19 A-loop — L870 HN, R840 O
20 A-loop — D871 O, R840 HE/HH12
21 A-loop D873 OD1/2, R897 HE —
22 A-loop — E876 OE1/2, R898 HE
23 A-loop D880, R897 D880, R897
24 A-loop K883 HZ1/2, E757 OE1 —
*Labels correspond to the numbered hydrogen bonds illustrated in Fig. 3.
ySalt bridges are highlighted in bold.Biophysical Journal 96(6) 2321–2334We extended the evaluation of hydrogen bonds to the
A-loop and aC helix because these regions undergo
the most pronounced structural shifts upon transition from
the inactive to the active state of the HER2 kinase. In similarity
to the hydrogen-bonding pattern in the C-loop, we observe
a considerable difference in the number of interactions in the
A-loop and aC helix of the active and inactive systems (see
Table 1 and Fig. 3). Specifically, there are four hydrogen
bonds and two salt bridges in the A-loop of the Y877-unphos-
phorylated inactive structure, compared with nine hydrogen
bonds and two salt bridges in the active A-loop. The aC helix
reflects a more marked distinction between the two systems:
two salt bridges occur in the active structure, whereas salt
bridges are entirely lacking in the inactive system. The
majority of bonds in the active system connect the key
domains of the kinase; for instance, the E766-K883 and
D769-R868 bonds link the A-loop and the aC helix
(Fig. 3 B). Furthermore, the R844-L866, N850-T862, V842-
R868, L852-K860, and L846-W888 bonds couple the A-loop
and C-loop. Hence, the network of specific hydrogen bonds
that bridge the key subregions of the kinase (A-loop, C-loop,
and aC helix) provides a rationale for the concerted motion
of these subdomains in the active state as depicted in Fig. 1.
Analysis of the stabilizing network of interactions
in the active and inactive kinase conformations
reveals a novel autoinhibitory mechanism
One of the most crucial interactions for kinase activation is
the salt bridge between E770 and K753, which is conserved
among ErbB family members (the analogous pair of residues
is E738-K721 in EGFR and E743-K726 in ErbB4; see Table
S1). This salt bridge is characteristic of the active conforma-
tions of kinases, as it facilitates catalysis by interacting with
the a- and b-phosphates of ATP (16). Indeed, the bridge is
lacking in inactive HER2 because the residues are seques-
tered by other amino acids. Specifically, K753 is salt-bridged
to D863 in the inactive state, preventing the interaction
between K753 and E770. It is noteworthy that an analogous
inhibitory bond, namely D836-K726, occurs in inactive
ErbB4 (see Table S3). We speculate that the autoinhibitory
bond, D863-K753, reflects a dual inhibitory mechanism.
Dynamics Simulations of HER2 Kinase 2327Not only does it sequester K753, it also engages D863, the
coordinating aspartate that facilitates rearrangement of the
substrate tyrosine and ATP. The D863-K753 bond is broken
in active HER2, allowing the crucial salt bridge to form and
freeing the coordinating aspartate for catalysis.
We identify a second autoinhibitory bond that impedes
formation of the E770-K753 salt bridge in the inactive state,
and note that this mechanism is shared by EGFR. In the inac-
tive EGFR conformation, E738 forms a salt bridge with
K836, which corresponds to R868 in HER2. Analogously,
R868 sequesters E770 in the inactive HER2 system;
however, in the active state, R868 bonds with V842 and
D769, allowing E770 to salt-bridge with K753 (see Table
S3). Hydrogen bonding of R868 to multiple residues ensures
release of E770 and promotion of the active state.
Variation among HER2, EGFR, and ErbB4
in the aC-b4 loop region of the kinase
In a recent study, Fan et al. (50) reported that HER2 is
strongly autoinhibited relative to EGFR and ErbB4, and
that a mechanism for the autoinhibition involves sequence
variation in a loop connecting the aC helix and the b4 sheet.
The HER2 kinase domain shares 83% sequence identity with
EGFR; in the aC-b4 loop, however, five of the eight residues
in HER2 differ from those in EGFR. Specifically, the polar
residues in the aC-b4 loop of EGFR are replaced by nonpolar
residues in HER2, which form a hydrophobic patch that
contacts another segment of hydrophobic residues located
in the A-loop. Residues comprising the hydrophobic patch
in HER2 include V773, M774, G776, V777, G778, and
V782 in the aC-b4 loop, and I861, T862, F864, L866, and
L869 in the A-loop. This hydrophobic motif has been inves-
tigated by several groups in relation to its association with
various molecules, such as the molecular chaperone Hsp90
(51,52). Fan et al. (50) postulated that the hydrophobic inter-
actions between the aC-b4 loop and the A-loop stabilize the
HER2 kinase in the inactive state, resulting in lower constitu-
tive catalytic activity relative to EGFR and ErbB4.In light of these experimental findings, we extended our
hydrogen-bonding analysis to the aC-b4 loop for HER2,
EGFR, and ErbB4. In tabulating the bonds for each system,
we observe that both the inactive and active HER2 structures
contain only two hydrogen bonds in the aC-b4 region
(Table 2). One of the bonds, S783-I861, is shared by both
systems and couples the aC-b4 loop to the A-loop. In
contrast, EGFR and ErbB4 contain a significantly greater
number of hydrogen bonds in the aC-b4 loop. The active
EGFR and ErbB4 structures form 10 and eight hydrogen
bonds, respectively (Table 2). Several bonds in active
EGFR, including H749-I829, C751-I829, and H749-V827,
link residues in the aC-b4 loop and the A-loop, whereas
other bonds, including S744-Y740, V745-V741, and L753-
M742, connect the aC-b4 loop and the aC helix. The active
HER2 system lacks many of these hydrogen bonds because
hydrophobic interactions, rather than hydrophilic contacts,
predominate in the aC-b4 region. In particular, the H749-
I829 and H749-V827 bonds are absent in HER2 because
the kinase contains a relatively nonpolar tyrosine residue in
the position analogous to the positively charged H749
in EGFR. Fig. 4 contrasts the network of hydrogen bonds
(in stick representation) in the aC-b4 loop of the active
EGFR system with the hydrophobic residues (in VDW repre-
sentation) in HER2. The individual bonds are labeled ac-
cording to the numbered residue pairs listed in Table 2.
The bonding analysis of the inactive ErbB systems reveals
a trend similar to that observed in the active systems. The
inactive EGFR and ErbB4 conformations contain four and
six hydrogen bonds, respectively, in contrast to two bonds
in the aC-b4 loop of inactive HER2 (Table 2). The lack of
hydrogen bonds in the aC-b4 loop of inactive HER2 is
consistent with the prominence of hydrophobic interactions
in this region as proposed by Fan et al. (50). Although it
shares similar bonding patterns with EGFR in the A-loop
and aC helix, HER2 differs markedly from EGFR in the
aC-b4 region due to the presence of the hydrophobic patch
of residues. The dearth of a hydrogen-bonding network
and the dominance of hydrophobic interactions surroundingTABLE 2 Comparison of the hydrogen-bonding network in the aC-b4 loop of HER2, EGFR, and ErbB4 kinases in active and inactive
conformations
Label* HER2 active EGFR active HER4 active HER2 inactive EGFR inactive HER4 inactive
1 — A743, L679 A748, Q684 — — —
2 — S744, N676 — — — —
3 — S744, Y740 S749, L745 G776, Y772 S744, Y740 S749, L745
4 — V745, V741 M750, I746 — — —
5 — — — — — M750, M747
6 G778, Y835 D746, Y803 — — — —
7 — — H752, Y808 — — H752, Y808
8 — H749, V827 — — — —
9 — H749, I829 H754, I834 — H749, I829 H754, I834
10 S783, I861 C751, I829 V756, I834 S783, I861 C751, I829 V756, I834
11 — R752, Q767 R757, Q772 — — —
12 — L753, M742 L758, M747 — L753, M742 L758, M747
*Labels correspond to the numbered hydrogen bonds illustrated in Fig. 4 B for EGFR kinase in the active conformation.Biophysical Journal 96(6) 2321–2334
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FIGURE 4 Contrast between the hydrophobic interac-
tions in HER2 and the hydrogen bonds in EGFR/ErbB4
in the aC-b4 loop. (A) The patch of hydrophobic residues
in the aC-b4 loop of the active HER2 structure. Residues in
the aC-b4 loop are colored green and residues in the
A-loop are colored orange (color online). (B) The
hydrogen-bonding network in the aC-b4 loop of the active
EGFR structure. The bonds are labeled according to the
numbering scheme in Table 2. (C) Sequence alignment
between HER2 and EGFR in the aC-b4 region of the
kinase. Blue arrows indicate residues contributing to the
hydrophobic patch in HER2.the aC-b4 loop in HER2 is thought to contribute to its inter-
action with the molecular chaperone Hsp90 (52). As a mature
protein, only HER2 among the members of the ErbB family
associates with Hsp90, as EGFR and ErbB4 lack the segment
of hydrophobic residues in the aC-b4 loop. It has been
proposed that binding of Hsp90 to the aC-b4 region in
HER2 provides an inhibitory mechanism for regulation of
HER2 activity by preventing dimerization and subsequent
activation of the HER2 kinase (51).
The hydrophobic association between HER2 and Hsp90 is
relevant to the effects of clinical mutations in the HER2
kinase domain. HER2 gene mutations have been identified
in a cohort of non-small cell lung cancers that involve in-
frame duplications/insertions within exon 20, a region that
corresponds to the aC-b4 loop in the kinase domain. The
most frequently occurring abnormality is the in-frame
YVMA insertion at residue G776 (G776YVMA), which has
been shown to undergo markedly higher tyrosine phosphor-
ylation than wild-type HER2, resulting in increased tumori-
genicity (14). Another prevalent activating mutation is
G776S, which has been found in gastric tumors (53). Such
mutations weaken the hydrophobic interactions surrounding
the aC-b4 loop and likely promote a hydrogen-bonding
network similar to those we have identified in EGFR and
ErbB4, which can disrupt the inhibitory stimulus provided
by HER2-Hsp90 association.
Heterodimerization with EGFR kinase destabilizes
the inactive conformation of HER2 kinase
As postulated by Zhang et al. (30), HER2 is likely to undergo
activation by the asymmetric dimer mechanism proposed for
EGFR. In the context of a HER2-EGFR heterodimer, the
residues comprising the dimeric interface for HER2 (kinase
undergoing activation) include P707, Q711, M712, I714,
L768, L790, and V794; for EGFR (activating kinase) they
include I917, Y920, M921, V924, M928, I929, and V956.
To investigate potential mechanisms of activation, we con-
structed a HER2-EGFR heterodimer in which EGFR is the
activator kinase and Y877-unphosphorylated inactive
HER2 is the activated kinase (see Fig. S5). The heterodimer
was modeled on the structure of the EGFR dimer generatedBiophysical Journal 96(6) 2321–2334by Zhang et al. (30) (see Methods). A second dimer was con-
structed in which the Y877-phosphorylated inactive HER2
monomer from the 10 ns equilibrated system was input as
the activated kinase. Both heterodimeric systems were
solvated and subjected to 20 ns of MD simulation (see
Methods). The objective was to determine whether dimeriza-
tion promotes the active state, and, if so, whether phosphor-
ylation of Y877 facilitates the activation mechanism.
PCA was performed for the 20 ns MD trajectories to char-
acterize the extent of correlation of atomistic fluctuations. As
was done for the monomeric systems, the active site region
was chosen to include the Ca atoms of the A-, C-, and
N-loops and the aC helix of HER2, the kinase that is under-
going activation in the context of the heterodimer. In simi-
larity to the inactive monomeric simulations, the principal
eigenmodes are dominated by A-loop movement (Fig. 5, A
and B). However, the phosphorylated heterodimer exhibits
notable fluctuations in the aC helix of HER2 (Fig. 5 B), in
similarity to the active monomeric structures. We also
observe a repositioning of the aC helix toward the active
conformation during the 20 ns MD simulation, shifting
from an RMSD of 2–6 A˚ relative to the inactive state
(Fig. 5 B and Fig. S6 D). The HER2 structure in the unphos-
phorylated dimer also exhibits a slight conformational rear-
rangement of its aC helix toward the active state in response
to the dimerization interface (Fig. 5 A).
As in our analysis of the monomeric systems, we aimed to
rationalize the pattern of global motions in the heterodimers
in terms of specific interactions. To identify stabilizing bonds
that are perturbed upon dimerization, we performed
a hydrogen-bonding analysis for the 20 ns MD trajectories.
An examination of the bonding network in the heterodimeric
systems reveals destabilization and severance of several
interactions present in the monomeric systems (Table 3). In
the dimer featuring Y877-unphosphorylated HER2 as the
activated kinase, several bonds responsible for maintaining
the inactive state in the monomer are broken, including
N764-S760 and Y772-G776 in the aC helix. Indeed, disrup-
tion of these bonds is expected as a result of their position
within the dimeric interface. Additional bonds that are
disturbed include G865-V842 and D873-R897 in the
A-loop. In the dimer involving Y877-phosphorylated
Dynamics Simulations of HER2 Kinase 2329HER2 as the activated kinase, several bonds expected to
break are indeed severed, including T759-E874, L785-
M774, and Y772-G776 in the aC helix. Key interactions
in the A-loop, such as G865-H843, R868-R840, and
V884-K887, have also been perturbed. Our findings indicate
that the dimerization interface directly alters the pattern of
stabilizing hydrogen bonds in the inactive system, in agree-
ment with the allosteric activation mechanism proposed by
Zhang et al. (30). The disruption of specific interactions in
the aC helix suggests that the pattern of hydrogen bonds
in the dimer is shifting away from the inactive state, and
that the kinase domain is more susceptible to perturbations
that would enable a conformational rearrangement toward
the active state. Moreover, the dimeric interface directly
induces the repositioning of the aC helix toward the active
conformation even on the relatively short timescale of 20 ns.
A
B
FIGURE 5 Global motions of the HER2-EGFR heterodimeric structures
as determined by PCA. The structures represent displacements along the first
eigenmode for (A) the Y877-unphosphorylated system and (B) the Y877-
phosphorylated system. The structures are color-coded according to the
RMSD (red and white indicate large fluctuations, blue indicates smaller
fluctuations) to illustrate the motions in individual residues (color online).
Insets reveal shifting of the aC helix in the dimer (blue) away from the inac-
tive conformation (green) and toward the active conformation (pink).Several bonds remain unperturbed by the dimerization
interface and hence may pose significant free energy barriers
to the conformational change accompanying activation. The
D863-K753 interaction, which is one of the salt bridges
involved in the dual autoinhibitory mechanism in the mono-
meric simulations, persists throughout the dimeric trajecto-
ries. We also note the importance of the K883-E757 bond,
which is conserved among all three inactive ErbB kinases,
in governing stabilization of the inactive structure, as it
must break in order for the K883-E766 salt bridge to
assemble in the active state.
FEP analysis of the role of Y877-phosphorylation
Several experimental studies have highlighted the impor-
tance of A-loop phosphorylation in HER2 activation. In
the Y877-phosphorylated active system, we identify
a network of hydrogen bonds that maintain the A-loop in
the open conformation: as the A-loop extends, it uncovers
the catalytic loop and promotes access of peptides to the
active site. The hydrogen bonds fasten the A-loop to
a segment of the aF helix (residues 896–901) and to the
region between the aE helix and the C-loop (residues
840–844), ensuring that the A-loop remains in the active
state (see Fig. S7). Three hydrogen bonds (L866-R844,
V842-R868, and R840-L870) secure the A-loop at its
N-terminal end (Fig. S7 B). Likewise, three bonds (Y877-
F899, A879-R897, and E876-R898) fasten the A-loop at
its C-terminal end (Fig. S7 C). It is noteworthy that several
of the bonds, such as L866-R844 and Y877-R844, link resi-
dues in the A-loop and C-loop, underscoring the tight
coupling of these regions in the active state. However, the
key residues required for kinase activity, D863 (the coordi-
nating aspartate) and D845 (the catalytic aspartate), do not
participate in the hydrogen-bonding network and hence
TABLE 3 Summary of broken and unbroken hydrogen bonds
in the MD trajectories for the HER2-EGFR heterodimers
Y877-unphosphorylated
dimer
Y877-phosphorylated
dimer
Proximal, broken* — T759-E874
N764-S760 —
Y772-G776 Y772-G776
— L785-M774
Proximal, unbrokeny K753-D863 K753-D863
E757-K883 E757-K883
L785-M774 —
Not proximal,
brokenz
G865-V842 —
— G865-H843
D873-R897 —
— V884-K887
*Refers to bonds containing residues that are proximal to the dimer interface
(within 3 A˚ of at least one of the dimeric interface residues for 75% of the
production trajectory) and have broken in the dimer trajectory.
yRefers to bonds containing residues that are proximal to the dimer interface
but have not broken in the dimer trajectory.
zRefers to bonds that are not proximal to the dimer interface but have broken
in the dimer trajectory.Biophysical Journal 96(6) 2321–2334
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propose an activation model in which residues neighboring
D863 and D845 compose hydrogen bonds that stabilize the
A-loop in the active state while ensuring the availability of
the catalytic aspartate residues for kinase activity.
Intriguingly, we observe that phosphorylated Y877
performs a key function in linking the network of hydrogen
bonds that maintain the A-loop in its extended form. The
phosphoryl group forms bonds with R844, K883, and
R868, thereby bridging the C- and N-terminal ends of the
A-loop (Fig. 6 A). Furthermore, the main-chain oxygen of
Y877 hydrogen-bonds with F899, contributing to the pattern
of fastening interactions in the A-loop. In contrast, fewer
hydrogen bonds occur in the A-loop of the Y877-unphos-
phorylated active system, indicating that the absence of the
phosphoryl group results in a decreased number of intra-
A-loop interactions (Fig. 6 B and Table S4). We define
a similar role for phosphorylated Y845 in the active EGFR
system. Y845-phosphorylated EGFR shares eight of nine
hydrogen bonds present in the A-loop of Y877-phosphory-
lated active HER2, including bonds between the phosphoryl
group and the A-loop (see Table S5). Our results for HER2
and EGFR suggest that the role of the phosphoryl group in
Y877 (or Y845 in EGFR) is to bridge the stabilizing bonds
on either side of the A-loop in the active system. In further
support of this bridging mechanism of phosphorylatedBiophysical Journal 96(6) 2321–2334Y877 in HER2 and Y845 in EGFR, we note an analogous
function for the phosphorylated tyrosine residue in insulin
receptor tyrosine kinase (IRK), for which there exists
a crystal structure of the phosphorylated active form of the
protein (54). The close alignment of the tyrosine-phosphory-
lated A-loops of EGFR, HER2, and IRK suggests a structural
role for the phosphorylated tyrosine as a bridging residue in
the respective active kinase conformations (see Fig. S8).
Analysis of the MD trajectories for the inactive systems
reveals that phosphorylation of Y877 promotes the forma-
tion of additional hydrogen bonds and salt bridges in the
A-loop (see Table S4). The phosphoryl group hydrogen-
bonds with R844 and K883, spanning the A-loop as it
does in the active system. Additional pairs of residues
include G865-H843 and R868-R840, which parallel L866-
R844 and R868-V842 in the active structure. Although phos-
phorylation of Y877 in the inactive system alters the
hydrogen-bonding pattern so that it more closely resembles
the network in the active system, phosphorylation is insuffi-
cient for promotion of conformational shifting to the active
state within the short timescale of our 10 ns simulations.
To further investigate the effect of Y877-phosphorylation
on kinase activity, we employed the FEP method to calculate
the Helmholtz free energy difference between the Y877-
unphosphorylated and Y877-phosphorylated states in the
NVT ensemble. The alchemical transformations wereFIGURE 6 (A) Snapshot of the Y877-phosphorylated
active system, illustrating the role of phosphorylated
Y877 in bridging the network of hydrogen bonds on either
side of the A-loop. The phosphoryl group forms bonds with
R844, K883, R868, and F899, thereby connecting the
N- and C-terminal ends of the A-loop. Hydrogen bonds
are depicted as blue dashed lines. (B) Snapshot of the
unphosphorylated active system, showing the lack of stabi-
lizing hydrogen bonds due to the absence of the phosphoryl
group.
Dynamics Simulations of HER2 Kinase 2331performed using the dual-topology paradigm (46), in which
the initial and the final states are defined in terms of distinct,
noninteracting topologies, and the interactions of the trans-
formed atoms with their environment are scaled in terms of
a linear parameter, l (see Methods for details). Four different
simulations were performed, including the transformation of
Y877 to pY877 in the unphosphorylated structures (inactive
and active), and the transformation of pY877 to Y877 in the
respective phosphorylated systems. Replacement of Y877
with phosphorylated Y877 resulted in a free energy change
of 385.1  1.2 kcal/mol for the active structure and
384.0  0.8 kcal/mol for the inactive structure, yielding
a DDF value of 1.1  1.4 kcal/mol (Fig. 7 A). The DF
values for the reverse transformation, pY877 to Y877,
were calculated in a similar manner, and were found to be
405.8  1.1 kcal/mol for the phosphorylated active structure
and 404.6  1.1 kcal/mol for the phosphorylated inactive
system, resulting in a DDF value of 1.2  1.5 kcal/mol
FIGURE 7 Evolution of the Helmholtz free energy as a function of the
coupling parameter l. FEP simulations were performed for (A) the transfor-
mation of Y877 to pY877 and (B) the transformation of pY877 to Y877 in
both the inactive and active systems. Phosphorylation of Y877 stabilizes the
inactive and active structures, whereas removal of the phosphoryl group
results in an increase in the free energy.(Fig. 7 B). The individual DF values for the forward and
reverse transformations differ slightly because the structures
contain different numbers of water molecules and ions, yet
the error estimates are within the ranges that have been
computed for other solvated systems (55–57). The DDF
values are significantly close and indicate that phosphoryla-
tion of Y877 provides a small increase in stability of the
active conformation relative to the inactive state, although
it is insufficient to significantly lower the kinase activation
barrier. Additional perturbations are required for full cata-
lytic competency of the kinase, suggesting that phosphoryla-
tion of Y877 is unlikely to be the primary stimulus for
conformational shifting to the active state.
It is noteworthy that differences in specific interactions
between phosphorylated and unphosphorylated systems iden-
tified in the FEP trajectories also appear in our hydrogen-
bonding analysis. In the active structure, replacement of
Y877 with pY877 produces several new hydrogen bonds,
including R844-Y877, K883-Y877, and R868-Y877, all of
which bridge the C- and N-terminal ends of the A-loop.
Toward the end of the transformation, the main-chain oxygen
of Y877 pairs with F899, which is consistent with the pattern
of hydrogen bonds highlighted in the previous section. The
perturbation of Y877 into pY877 in the inactive system
effects formation of additional hydrogen bonds, such as
R844-Y877 and K883-Y877, which link the ends of the
A-loop as they do in the active system. Thus, the FEP results
are consistent with our hydrogen-bonding analysis, validating
the robustness of the identified interactions despite the differ-
ences in simulation protocols.
DISCUSSION AND CONCLUSION
Given the involvement of the ErbB receptor tyrosine kinases
in a wide range of human diseases, including schizophrenia
and various types of cancer (2), it is imperative to understand
their mechanism of activation at the molecular level. In this
study we investigated the mechanisms that are important in
HER2 kinase domain regulation and compared them with
two other ErbB family members, EGFR and ErbB4, to deter-
mine the molecular basis for HER2’s unique mode of activa-
tion. Our MD simulations provide us with a framework for
studying the atomistic behavior of the HER2 kinase domain
in both monomeric and dimeric contexts. We characterized
the global motions of the HER2 systems using PCA and
rationalized the differences in fluctuations in terms of
specific interactions, namely, salt bridges and hydrogen
bonds. Specifically, the existence of an extensive bonding
network among the four key domains of the kinase in its
active state correlates with the concerted motions of the
four main loops as revealed by the PCA. The tight coupling
of the A-loop and C-loop in the active system is especially
pronounced, leading us to postulate the significance of the
interaction in alignment of the catalytic residues. We also
identify several commonalities in hydrogen-bonding patternsBiophysical Journal 96(6) 2321–2334
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helix. One such conserved pattern involves the sequestration
of D863 (the coordinating aspartate), K753, and E770 in the
inactive state, preventing formation of the K753-E770 salt
bridge and release of D863 for catalysis. We postulate that
this mechanism reflects a means of dual autoinhibition, as
both the coordinating aspartate and the crucial salt bridge
are sequestered in the inactive state. Despite these shared
trends in hydrogen bonds in key loops required for activa-
tion, the bonding pattern in HER2 differs markedly in the
aC-b4 loop. HER2 lacks many of the hydrogen bonds that
occur in the aC-b4 loop in EGFR and ErbB4 due to the pres-
ence of the patch of hydrophobic residues in the aC-b4
region. The unique hydrogen-bonding network in the aC-b4
loop in HER2 is relevant to the putative hydrophobic inter-
action between HER2 and the molecular chaperone Hsp90.
The association between HER2 and Hsp90 serves a regula-
tory role in preventing HER2 dimerization and subsequent
activation (51). Unlike the other ErbB family members, the
extracellular domain of HER2 is poised for dimerization in
the absence of ligand binding (23), rationalizing the require-
ment for such tight regulatory mechanisms. The decrease in
hydrophobic character and concomitant increase in the
degree of hydrogen bonding in the aC-b4 region of several
clinically identified HER2 mutants alters the mutant HER2
bonding patterns in similarity to those of EGFR and
ErbB4. Such mutations are expected to be activating by dis-
rupting the HER2-Hsp90 association.
The analysis of global motions and hydrogen-bonding
patterns was extended to a HER2-EGFR heterodimer. MD
simulations of the heterodimeric systems result in destabili-
zation of several bonds present in the inactive monomeric
structures, including interactions in the aC helix, as the aC
helix comprises much of the dimerization interface for the
activated kinase. The disruption of the hydrogen-bonding
pattern in both Y877-phosphorylated and Y877-unphos-
phorylated heterodimers provides a rationale for the
observed conformational rearrangement of the aC helix
toward the active state. Furthermore, we identify several
interactions that persist throughout the dimeric trajectories
of the inactive states and are hence candidates for further
investigation using free energy methods such as umbrella
sampling simulations, as the molecular environment
surrounding such residues may define the pathway for
conformational change and the associated barriers to activa-
tion. Since the residues involved in the N- and C-lobe faces
of the dimer are essentially invariant among the ErbB family
members, our results can in principle be extended to predict
the behavior of other ErbB heterodimers.
We also investigated the effect of phosphorylation of the
regulatory tyrosine residue, Y877, on kinase activation.
The results of our FEP simulations support the hypothesis
that phosphorylation of Y877 is unlikely to provide a domi-
nant stimulus for activation. However, our structural and
hydrogen-bonding analyses of the MD trajectories stronglyBiophysical Journal 96(6) 2321–2334suggest that phosphorylated Y877 contributes to the network
of fastening bonds in the A-loop by bridging the stabilizing resi-
dues at the C- and N-terminal ends of the loop, thereby consid-
erably altering the conformational environment surrounding the
A-loop. Consistent with these findings, although phosphoryla-
tion of the analogous A-loop tyrosine residue Y845 is unneces-
sary for catalytic activity of EGFR, it is known to significantly
alter downstream signaling events, including activation of
STAT5b and EGF-induced DNA synthesis (58,59). Like-
wise, Ishizawar et al. (60) postulated a role for phosphorylated
Y877 in enhancing HER2-ErbB3 heterodimer formation by
potentially changing the conformation of the kinase and
engaging other molecules. Hence the involvement of phos-
phorylated Y877 in the network of fastening interactions in
the A-loop and the resultant alteration in the conformational
environment may influence recruitment of signaling media-
tors involved in mitogenesis and other downstream processes.
We also note that the residues involved in fastening the
A-loop, which include R897, R898, and F899 in the aF helix,
warrant further investigation because mutation of these resi-
dues may destabilize the fastening bonding network, and
this effect may further elucidate the role of Y877-phosphory-
lation in HER2. These predictions can be experimentally
tested and validated with the use of HER2 mutation assays.
The protein kinase genes are among the most frequently
mutated genes in human cancers, and several HER2 kinase
domain mutants have been determined. Our simulations
provide insight into the effect of these mutations in the
aC-b4 loop region of the HER2 kinase through assessment
of structural dynamics and hydrogen-bonding patterns in
the kinase domain. Furthermore, we predict the importance
of previously overlooked regions, such as the segment of
residues directly preceding the aF helix, in regulation of
kinase activation. Our results are consistent with a large
body of experimental data (29,30,50,52,54) and provide
a framework for highlighting the most crucial bonding inter-
actions in the monomeric and dimeric HER2 systems. Eluci-
dation of the molecular regulatory mechanisms will help
establish structure-function relationships in the wild-type
HER2 kinase, as well as predict mutations with a propensity
for constitutive activation. Such molecular variants in HER2
receptors are known to profoundly impact specific therapies
targeting HER2-mediated cancers.
SUPPORTING MATERIAL
Figures, movies, and tables are available at http://www.biophysj.org/
biophysj/supplemental/S0006-3495(09)00373-7.
We thank Mark A. Lemmon, Sung Hee Choi, and Andrew Shih for several
helpful discussions, and Pe´ter Bagossi for providing the PDB coordinates for
the HER2 model.
We acknowledge funding from the National Science Foundation through
grant NSF CBET-0730955. Shannon Telesco received support through
a Graduate Research Fellowship from the National Science Foundation and
a Graduate Assistantship in Areas of National Need from the Bioengineering
Dynamics Simulations of HER2 Kinase 2333Department of the University of Pennsylvania. Computational resources were
provided in part by the National Partnership for Advanced Computational
Infrastructure through allocation MCB060006.
REFERENCES
1. Schlessinger, J. 2000. Cell signaling by receptor tyrosine kinases. Cell.
103:211–225.
2. Linggi, B., and G. Carpenter. 2006. ErbB receptors: new insights on
mechanisms and biology. Trends Cell Biol. 16:649–656.
3. Yarden, Y., and M. X. Sliwkowski. 2001. Untangling the ErbB signal-
ling network. Nat. Rev. Mol. Cell Biol. 2:127–137.
4. Schulze, W. X., L. Deng, and M. Mann. 2005. Phosphotyrosine
interactome of the ErbB-receptor kinase family. Mol. Syst. Biol. 1:
2005.0008.
5. Citri, A., and Y. Yarden. 2006. EGF-ERBB signalling: towards the
systems level. Nat. Rev. Mol. Cell Biol. 7:505–516.
6. Choi, S. H., J. M. Mendrola, and M. A. Lemmon. 2007. EGF-indepen-
dent activation of cell-surface EGF receptors harboring mutations found
in gefitinib-sensitive lung cancer. Oncogene. 26:1567–1576.
7. Ji, H., D. Li, L. Chen, T. Shimamura, S. Kobayashi, et al. 2006. The
impact of human EGFR kinase domain mutations on lung tumorigenesis
and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 9:485–
495.
8. Lee, J. W., Y. H. Soung, S. Y. Kim, S. W. Nam, W. S. Park, et al. 2006.
ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
Cancer Lett. 237:89–94.
9. Minami, Y., T. Shimamura, K. Shah, T. LaFramboise, K. A. Glatt, et al.
2007. The major lung cancer-derived mutants of ERBB2 are oncogenic
and are associated with sensitivity to the irreversible EGFR/ERBB2
inhibitor HKI-272. Oncogene. 26:5023–5027.
10. Shigematsu, H., T. Takahashi, M. Nomura, K. Majmudar, M. Suzuki,
et al. 2005. Somatic mutations of the HER2 kinase domain in lung
adenocarcinomas. Cancer Res. 65:1642–1646.
11. Willmore-Payne, C., J. A. Holden, and L. J. Layfield. 2006. Detection of
epidermal growth factor receptor and human epidermal growth factor
receptor 2 activating mutations in lung adenocarcinoma by high-resolu-
tion melting amplicon analysis: correlation with gene copy number,
protein expression, and hormone receptor expression. Hum. Pathol.
37:755–763.
12. Willmore-Payne, C., J. A. Holden, and L. J. Layfield. 2006. Detection of
EGFR- and HER2-activating mutations in squamous cell carcinoma
involving the head and neck. Mod. Pathol. 19:634–640.
13. Slamon, D. J., W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, et al.
1989. Studies of the HER-2/neu proto-oncogene in human breast and
ovarian cancer. Science. 244:707–712.
14. Wang, S. E., A. Narasanna, M. Perez-Torres, B. Xiang, F. Y. Wu, et al.
2006. HER2 kinase domain mutation results in constitutive phosphory-
lation and activation of HER2 and EGFR and resistance to EGFR tyro-
sine kinase inhibitors. Cancer Cell. 10:25–38.
15. Huse, M., and J. Kuriyan. 2002. The conformational plasticity of protein
kinases. Cell. 109:275–282.
16. Stamos, J., M. X. Sliwkowski, and C. Eigenbrot. 2002. Structure of
the epidermal growth factor receptor kinase domain alone and in
complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem.
277:46265–46272.
17. Hubbard, S. R., and J. H. Till. 2000. Protein tyrosine kinase structure
and function. Annu. Rev. Biochem. 69:373–398.
18. Tice, D. A., J. S. Biscardi, A. L. Nickles, and S. J. Parsons. 1999. Mech-
anism of biological synergy between cellular Src and epidermal growth
factor receptor. Proc. Natl. Acad. Sci. USA. 96:1415–1420.
19. Bose, R., H. Molina, A. S. Patterson, J. K. Bitok, B. Periaswamy, et al.
2006. Phosphoproteomic analysis of Her2/neu signaling and inhibition.
Proc. Natl. Acad. Sci. USA. 103:9773–9778.20. Zhang, H. T., D. M. O’Rourke, H. Zhao, R. Murali, Y. Mikami, et al.
1998. Absence of autophosphorylation site Y882 in the p185neu onco-
gene product correlates with a reduction of transforming potential.
Oncogene. 16:2835–2842.
21. Xu, W., X. Yuan, K. Beebe, Z. Xiang, and L. Neckers. 2007. Loss of
Hsp90 association up-regulates Src-dependent ErbB2 activity. Mol.
Cell. Biol. 27:220–228.
22. Cho, H. S., and D. J. Leahy. 2002. Structure of the extracellular region
of HER3 reveals an interdomain tether. Science. 297:1330–1333.
23. Cho, H. S., K. Mason, K. X. Ramyar, A. M. Stanley, S. B. Gabelli, et al.
2003. Structure of the extracellular region of HER2 alone and in
complex with the Herceptin Fab. Nature. 421:756–760.
24. Ferguson, K. M., M. B. Berger, J. M. Mendrola, H. S. Cho, D. J. Leahy,
et al. 2003. EGF activates its receptor by removing interactions that
autoinhibit ectodomain dimerization. Mol. Cell. 11:507–517.
25. Garrett, T. P., N. M. McKern, M. Lou, T. C. Elleman, T. E. Adams,
et al. 2003. The crystal structure of a truncated ErbB2 ectodomain
reveals an active conformation, poised to interact with other ErbB recep-
tors. Mol. Cell. 11:495–505.
26. Garrett, T. P., N. M. McKern, M. Lou, T. C. Elleman, T. E. Adams,
et al. 2002. Crystal structure of a truncated epidermal growth factor
receptor extracellular domain bound to transforming growth factor a.
Cell. 110:763–773.
27. Wood, E. R., A. T. Truesdale, O. B. McDonald, D. Yuan, A. Hassell,
et al. 2004. A unique structure for epidermal growth factor receptor
bound to GW572016 (Lapatinib): relationships among protein confor-
mation, inhibitor off-rate, and receptor activity in tumor cells. Cancer
Res. 64:6652–6659.
28. Bouyain, S., P. A. Longo, S. Li, K. M. Ferguson, and D. J. Leahy. 2005.
The extracellular region of ErbB4 adopts a tethered conformation in the
absence of ligand. Proc. Natl. Acad. Sci. USA. 102:15024–15029.
29. Qiu, C., M. K. Tarrant, S. H. Choi, A. Sathyamurthy, R. Bose, et al.
2008. Mechanism of activation and inhibition of the HER4/ErbB4
kinase. Structure. 16:460–467.
30. Zhang, X., J. Gureasko, K. Shen, P. A. Cole, and J. Kuriyan. 2006. An
allosteric mechanism for activation of the kinase domain of epidermal
growth factor receptor. Cell. 125:1137–1149.
31. Fiser, A., R. K. Do, and A. Sali. 2000. Modeling of loops in protein
structures. Protein Sci. 9:1753–1773.
32. Sali, A., and T. L. Blundell. 1993. Comparative protein modelling by
satisfaction of spatial restraints. J. Mol. Biol. 234:779–815.
33. MacKerell, A. D., Jr., D. Bashford, M. Bellott, R. L. Dunbrack,
J. D. Evanseck, et al. 1998. All-atom empirical potential for molecular
modeling and dynamics studies of proteins. J. Phys. Chem. B.
102:3586–3616.
34. Bagossi, P., G. Horvath, G. Vereb, J. Szollosi, and J. Tozser. 2005.
Molecular modeling of nearly full-length ErbB2 receptor. Biophys. J.
88:1354–1363.
35. Laskowski, R. A., M. W. MacArthur, D. S. Moss, and J. M. Thornton.
1993. PROCHECK: a program to check the stereochemical quality of
protein structures. J. Appl. Cryst. 26:283–291.
36. Jorgensen, W. L., J. Chandrasekar, J. Madura, R. Impey, and M. Klein.
1983. Comparison of simple potential functions for simulating liquid
water. J. Chem. Phys. 79:926–935.
37. Grubmuller, H., B. Heymann, and P. Tavan. 1996. Ligand binding:
molecular mechanics calculation of the streptavidin-biotin rupture force.
Science. 271:997–999.
38. Phillips, J. C., R. Braun, W. Wang, J. Gumbart, E. Tajkhorshid, et al.
2005. Scalable molecular dynamics with NAMD. J. Comput. Chem.
26:1781–1802.
39. Essmann, U. 1995. A smooth particle mesh Ewald method. J. Chem.
Phys. 103:8577–8593.
40. Andersen, H. C. 1983. Rattle: a ‘‘velocity’’ version of the shake algo-
rithm for molecular dynamics calculations. J. Comput. Phys. 52:24–34.Biophysical Journal 96(6) 2321–2334
2334 Telesco and Radhakrishnan41. Feller, S. E., Y. Zhang, R. W. Pastor, and B. R. Brooks. 1995. Constant
pressure molecular dynamics simulation: The Langevin piston method.
J. Chem. Phys. 103:4613–4621.
42. Humphrey, W., A. Dalke, and K. Schulten. 1996. VMD: visual
molecular dynamics. J. Mol. Graph. 14:33–38, 27–28.
43. Glykos, N. M. 2006. Software news and updates. CARMA: a molecular
dynamics analysis program. J. Comput. Chem. 27:1765–1768.
44. Zwanzig, R. W. 1954. High-temperature equation of state by a perturba-
tion method. I. Nonpolar gases. J. Chem. Phys. 22:1420–1426.
45. Bhandarkar, M., R. Brunner, C. Chipot, A. Dalke, S. Dixit, et al. 2005.
NAMD user’s guide, version 2.6b1. Theoretical Biophysics Group,
University of Illinois and Beckman Institute, Urbana, IL.
46. Gao, J., K. Kuczera, B. Tidor, and M. Karplus. 1989. Hidden thermody-
namics of mutant proteins: a molecular dynamics analysis. Science.
244:1069–1072.
47. Pitera, J. W., and W. F. van Gunsteren. 2002. A comparison of non-
bonded scaling approaches for free energy calculations. Mol. Simul.
28:45–65.
48. Beutler, T. C., A. E. Mark, R. C. van Schaik, P. R. Gerber, and
W. F. van Gunsteren. 1994. Avoiding singularities and neumerical
instabilities in free energy calculations based on molecular simulations.
Chem. Phys. Lett. 222:529–539.
49. Shih, A. J., J. Purvis, and R. Radhakrishnan. 2008. Molecular
systems biology of ErbB1 signaling: bridging the gap through multi-
scale modeling and high-performance computing. Mol. Biosyst.
4:1151–1159.
50. Fan, Y. X., L. Wong, J. Ding, N. A. Spiridonov, R. C. Johnson, et al.
2008. Mutational activation of ErbB2 reveals a new protein kinase
autoinhibition mechanism. J. Biol. Chem. 283:1588–1596.Biophysical Journal 96(6) 2321–233451. Citri, A., J. Gan, Y. Mosesson, G. Vereb, J. Szollosi, et al. 2004. Hsp90
restrains ErbB-2/HER2 signalling by limiting heterodimer formation.
EMBO Rep. 5:1165–1170.
52. Xu, W., X. Yuan, Z. Xiang, E. Mimnaugh, M. Marcu, et al. 2005.
Surface charge and hydrophobicity determine ErbB2 binding to the
Hsp90 chaperone complex. Nat. Struct. Mol. Biol. 12:120–126.
53. Stephens, P., C. Hunter, G. Bignell, S. Edkins, H. Davies, et al. 2004.
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature.
431:525–526.
54. Hubbard, S. R. 1997. Crystal structure of the activated insulin receptor
tyrosine kinase in complex with peptide substrate and ATP analog.
EMBO J. 16:5572–5581.
55. Henin, J., B. Maigret, M. Tarek, C. Escrieut, D. Fourmy, et al. 2006.
Probing a model of a GPCR/ligand complex in an explicit membrane
environment: the human cholecystokinin-1 receptor. Biophys. J.
90:1232–1240.
56. Donnini, S., A. E. Mark, A. H. Juffer, and A. Villa. 2005. Incorporating
the effect of ionic strength in free energy calculations using explicit
ions. J. Comput. Chem. 26:115–122.
57. Zhou, R., P. Das, and A. K. Royyuru. 2008. Single mutation induced
H3N2 hemagglutinin antibody neutralization: a free energy perturbation
study. J. Phys. Chem. B. 112:15813–15820.
58. Boerner, J. L., J. S. Biscardi, C. M. Silva, and S. J. Parsons. 2005. Trans-
activating agonists of the EGF receptor require Tyr 845 phosphorylation
for induction of DNA synthesis. Mol. Carcinog. 44:262–273.
59. Kloth, M. T., K. K. Laughlin, J. S. Biscardi, J. L. Boerner, S. J. Parsons,
et al. 2003. STAT5b, a mediator of synergism between c-Src and the
epidermal growth factor receptor. J. Biol. Chem. 278:1671–1679.
60. Ishizawar, R. C., T. Miyake, and S. J. Parsons. 2007. c-Src modulates
ErbB2 and ErbB3 heterocomplex formation and function. Oncogene.
26:3503–3510.
